StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
AKTSBullishEarningsnews
High materiality8/10

Aktis reports ASCO AKY-2519 data; strong cash runway into 2029 with multiple near-term milestones

Aug 13, 2026, 4:08 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive data from AKY-2519 at ASCO, strong cash runway into 2029, and near-term milestones (AKY-1189 data in 1Q2027; AKY-2519 activities in 2H2026) could attract buyers and lift AKTS shares, despite typical biotech execution risk.

AI summary

What happened, with direct paths to the underlying reporting

Aktis Oncology posted Q2 2026 results showcasing AKY-2519 imaging data at ASCO, ongoing AKY-1189 enrollment, and planned initiation of AKY-2519 BActinium-2 in 2H 2026. The company also disclosed a cash balance of $517.3M, runway into 2029, and progress toward an in-house GMP facility by 2H 2026, setting up a data-rich 2027 and beyond for its radiopharmaceutical pipeline.

  • AKY-2519 imaging data at ASCO shows robust tumor uptake and wide therapeutic window.
  • AKY-1189 enrollment continues in NECTINIUM-2 Phase 1b across Nectin-4 tumors.
  • AKY-2519 Phase 1b BActinium-2 starts in H2 2026; AKY-1189 data expected 1Q2027.
  • Cash, cash equivalents, and marketable securities: $517.3M; runway to 2029; GMP facility by 2H2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event